OZOla M Abu Zeid

Ola M Abu Zeid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ola M Abu Zeid has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • D.M. Abdel Halim

    Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt

    2 shared publications
  • S.M. Esmat

    Department of Dermatology Faculty of Medicine Cairo University Cairo Egypt

    2 shared publications
  • A.M. El‐Tawdy

    Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • Dina El Sharkawy

    Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • G.A. Hafez

    Department of Pathology, Faculty of Medicine, Suez Canal University, Suez, Egypt

    1 shared publication
  • Khadiga Sayed

    Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication

Latest Publications

  • Expression of microRNA 205 3p and 205 5p in basal cell carcinoma and squamous cell carcinoma in the Egyptian population: a pilot case–control study

    by Ola M Abu Zeid, Sharif ElBehairy, Zeiad Gad, Laila Rashed, Khadiga Sayed

    Background Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are non-melanoma skin cancer (NMSC). microRNAs (miRNAs) are short single-stranded post-transcriptional regulatory RNAs that are known to play significant roles in cell development, differentiation, and cancer development. miR-205 has been found to be dysregulated in some tumors in humans. Objective To assess the tissue expression of miR-205 3p and 5p, as oncogenes, in BCC and SCC. Patients and Methods This case-control study included 21 patients with BCC, 21 patients with SCC and 21 healthy controls. Tissue expressions of miR-205 3p and 5p were evaluated using Real Time PCR technique. Results Tissue expressions of miR-205 3p and 5p were significantly higher in BCC and SCC compared to controls with a significantly higher expression of miR-205 3p than the 5p arm in both BCC and SCC. Moreover, the expressions of both arms were significantly higher in SCC compared to BCC. Conclusion miR-205 3p and 5p seemed to have an oncogenic effect in BCC and SCC with the 3p arm contributing more to this oncogenic effect. This oncogenic effect could be through miR-205 3p and 5p targeting and inhibiting tumor suppressor proteins in skin cells.

  • The efficacy of combining fractional CO2 laser and tacrolimus ointment in the treatment of vitiligo

    by Ola M Abu Zeid, Noha Omar, Dina El Sharkawy

    Background Treatment of vitiligo is very challenging. Topical tacrolimus is one of the topical modalities reported to be successful. No single treatment, however, gives on its own satisfactory results, and combination treatments offer better outcomes. Fractional CO2 laser (FCO2) has been recently studied as an adjuvant treatment with other modalities in vitiligo. Objective To evaluate the value of adding FCO2 laser before tacrolimus ointment in vitiligo. Patients and methods This is a randomized controlled prospective clinical trial including 27 patients with stable vitiligo with a total of 152 lesions. Lesions on one side of the body received one session of FCO2 every month for 3 months in addition to tacrolimus ointment twice daily for 3 months, whereas lesions on the other side of the body received tacrolimus ointment only. Results Lesions treated with the combination modality showed improvement in 17 (22.36%) lesions, with a mean reduction in Vitiligo Area Scoring Index (VASI) of 10.05%, whereas lesions treated with tacrolimus only showed improvement in 13 (17.1%) lesions, with a mean reduction in VASI of 5.535%, yet these differences were not statistically significant (P=0.46 and 0.24, respectively). Acral lesions showed significantly more reduction in VASI when treated with combination therapy than with tacrolimus only (P=0.034). Lesions with shorter duration showed significant more reduction in VASI scores when treated with the combination (P=0.024). Conclusion Treatment of stable vitiligo with FCO2 before tacrolimus yields mild improvement, statistically not significantly better than tacrolimus only except in acral areas. Lesions of shorter duration show significantly better response to the combination treatment than to tacrolimus only.


  • Tissue expression of aquaporin 3 in different sites of vitiligo: an immunohistochemical study

    by S.M. Esmat, O.A. Zeid, D.M. Abdel Halim, M.T. Fawzy, M. Abdel Latif, V. Lazarova, M. Assaf


  • Acral lesions of vitiligo: why are they resistant to photochemotherapy?

    by S.M. Esmat, A.M. El‐Tawdy, G.A. Hafez, O.A. Zeid, D.M. Abdel Halim, M.A. Saleh, T.M. Leheta, M. ElMofty

    Background  Acral lesions of vitiligo are usually resistant to conventional lines of treatment as well as surgical interventions.Objective  To clarify causes underlying resistance of acral lesions to pigmentation in vitiligo by studying some of the factors associated with mechanisms of repigmentation following photochemotherapy.Methods  The study included twenty patients with active vitiligo. Skin biopsies were taken from lesional and perilesional skin of areas expected to respond (trunk and proximal limb) and skin of acral areas, before and after PUVA therapy. Sections were stained with H and E, Melan‐A, MHCII, CD1a, SCF and c‐kit protein.Results  Before treatment acral areas showed significantly lower hair follicle density, melanocyte density, Langerhans cell (LC) density, epidermal MHCII expression, lesional SCF expression and perilesional c‐kit expression. Following treatment with PUVA in both non‐responsive acral and repigmenting non‐acral lesions identical immunohistochemical changes in the form of significant decrease in LC density, epidermal MHC‐II and SCF expression were observed.Conclusion  The surprisingly similar histochemical changes in response to PUVA in acral and non‐acral lesions did not manifest with clinical repigmentation except in non‐acral ones. Factors such as inherent lower melanocyte density, lower melanocyte stem cell reservoirs and/or lower baseline epidermal stem cell factor may be considered as possible play makers in this respect.